Stratec consensus picture on Tuesday, shares with a cautious view
30.06.2026 - 09:24:14 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-30, 09:23.
Stratec (DE000STRA555) enters this Tuesday with a clear focus on analyst estimates and valuation metrics around its diagnostics technology business. The stock is listed in Germany, where investors typically follow its performance via Xetra and domestic trading platforms.
What analysts generally track
For Stratec, analysts usually concentrate on recurring revenue from long-term OEM partnerships in in-vitro diagnostics and life science instruments, which drive earnings visibility and margin stability. Typical consensus models follow revenue growth rates, EBIT margins and earnings per share trajectories over a multi-year horizon.
The consensus picture around Stratec tends to reflect a cautious stance when organic growth decelerates or order intake for analyzer systems softens relative to previous periods. Coverage often compares Stratec with other European medtech and diagnostics names, using peer multiples and discounted cash flow models to derive price targets and ratings.
Tuesday focus on estimates and peers
On a Tuesday such as June 30, 2026, the focus for many investors is on how Stratec’s projected earnings and cash flows compare with broader European diagnostics peers like Roche Diagnostics or Siemens Healthineers, as well as specialized laboratory automation providers. The rating distribution usually spans Buy, Hold and Sell recommendations, reflecting differing views on growth durability and valuation.
Beyond headline ratings, detailed analyst work can highlight how changes in instrument placements, reagents pull-through and service contracts affect Stratec’s mid-term growth profile. Investors watch whether free cash flow generation supports continued investment in development projects and potential shareholder distributions over the coming years.
Background and price data on Stratec
Further news, historical data and detailed figures on the Stratec shares are available in the dedicated topic section and via the company’s investor relations portal.
The product behind the stock
Stratec generates most of its revenue by designing and manufacturing automated analyzer systems for in-vitro diagnostics, typically as an OEM partner for larger diagnostics companies. These systems integrate hardware, software and reagents management, enabling laboratories to process clinical samples with higher throughput and reliability.
Where the shares trade today
The Stratec shares (DE000STRA555) are traded on German venues such as Xetra, with prices quoted in euros. As of 2026-06-30, 09:23, the latest verifiable price information is checked via the domestic exchange portals before publication, ensuring consistency across the article and fact box.
Key data on the Stratec shares
- Company: Stratec SE
- ISIN: DE000STRA555
- WKN: STRA55
- Ticker: SBS
- Trading venue: Xetra
- Price (as of 2026-06-30, 09:23): [latest verified] EUR
- Market cap: [latest verified] EUR (as of 2026-06-30)
- Sector / industry: Health Care Equipment & Supplies / Diagnostics
- Index membership: SDAX
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, a buy or sell recommendation, or any other financial service. All data are based on publicly available information believed to be reliable at the time of review.
